Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

OS Therapies Incorporated Common Stock (NY:OSTX)

1.800 -0.030 (-1.64%)

Official Closing Price Updated: 8:00 PM EDT, Jun 3, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	624,687
Open	1.830
Bid (Size)	1.810 (300)
Ask (Size)	1.870 (300)
Prev. Close	1.830
Today's Range	1.760 - 1.870
52wk Range	1.150 - 2.570
Shares Outstanding	5,847,955
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

OS Therapies Achieves Statistically Significant 2.5-Year Overall Survival in Phase 2b Trial of OST-HER2 in Fully Resected Pulmonary Metastatic Osteosarcoma

June 02, 2026

75% 2.5-year overall survival for OST-HER2 vs. 47% pooled historical control ...

Via Newsfile

OS Therapies Announces the Publication of Four Articles on OST-HER2 and Osteosarcoma in Drug Discovery World

May 29, 2026

The Company confirms that it will release 2.5 year overall survival data from Phase 2b clinical trial OST-HER2 in the...

Via Newsfile

Performance

YTD	+34.3%	+34.3%
1 Month	+8.4%	+8.4%
3 Month	+22.4%	+22.4%
6 Month	+2.9%	+2.9%
1 Year	+13.2%	+13.2%

More News

OS Therapies to Attend Upcoming Medical, Financial and Industry Conferences

May 26, 2026

Via Newsfile

OS Therapies Reports First Quarter 2026 Financials and Provides Business Update

May 18, 2026

Via Newsfile

OS Therapies to Announce First Quarter 2026 Financials on Monday, May 18, 2026

May 15, 2026

Via Newsfile

OS Therapies Appoints Industry Leader Dr. Craig Eagle as Chief Medical Advisor

May 14, 2026

Via Newsfile

Stonegate Capital Partners Updates Coverage on OS Therapies Inc. (OSTX)

May 12, 2026

Via Newsfile

OS Therapies Announces EMA Initiates Rolling Review of Conditional Marketing Authorization Application for OST-HER2 in the Prevention or Delay of Recurrence in Fully Resected Pulmonary Metastatic Osteosarcoma

April 30, 2026

Via Newsfile

OS Therapies Schedules OST-HER2 Pharmacodynamic Response Biomarker Conference Call on April 30, 2026 at 8:30am ET

April 27, 2026

Via Newsfile

OS Therapies Files New Patent Application Covering Biomarkers of the Immune Response to Listeria Monocytogenes

April 16, 2026

Via Newsfile

OS Therapies Appoints Biotech Industry Luminary Robert "Bob" S. Langer, PhD as Strategic Advisor

April 13, 2026

Via Newsfile

OS Therapies Investor News: Rosen Law Firm Encourages OS Therapies Incorporated Investors to Inquire About Securities Class Action Investigation – OSTX

April 11, 2026

From The Rosen Law Firm, P.A.

Via Business Wire

Rosen Law Firm Encourages OS Therapies Incorporated Investors to Inquire About Securities Class Action Investigation – OSTX

April 10, 2026

From The Rosen Law Firm, P.A.

Via Business Wire

OS Therapies Appoints Craig Eagle, MD as Strategic Advisor

April 08, 2026

Via Newsfile

OS Therapies Completes $5.25M Registered Direct Offering Primarily with Pre-Existing High-Net-Worth Investors

April 02, 2026

Via Newsfile

OS Therapies Completes Submission of Biomarker & Clinical Data for U.S. FDA Pre-BLA Meeting, Reports Full Year 2025 Financial Results and Provides Business Update

March 31, 2026

Via Newsfile

OS Therapies Granted Meetings with U.S. FDA, U.K. MHRA, EMA and Australian Therapeutic Goods Administration to Review Global Confirmatory Phase 3 Trial for OST-HER2 in Metastatic Osteosarcoma

March 27, 2026

Via Newsfile

OS Therapies Granted EMA's Advanced Therapy Medicinal Product (ATMP) Designation for OST-HER2 in the Treatment of Pulmonary Recurrence in Resected Osteosarcoma

March 25, 2026

Via Newsfile

Get insights into the top gainers and losers of Thursday's after-hours session. ↗

March 19, 2026

Via Chartmill

OS Therapies Announces FDA OST-HER2 Type D Meeting Elevated to Type B Pre-BLA Meeting

March 09, 2026

Via Newsfile

OS Therapies Provides Global Regulatory Update for OST-HER2 in Recurrent, Fully Resected, Pulmonary Metstatic Osteosarcoma ↗

February 17, 2026

Via Newsfile

OS Therapies Applauds Reauthorization of Pediatric Priority Review Voucher Program to Advance Breakthrough Osteosarcoma Immunotherapies

February 04, 2026

Via Newsfile

OS Therapies Initiates US FDA BLA Filing for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

February 02, 2026

Via Newsfile

OS Therapies Announces Positive Biomarker Data from Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

January 15, 2026

Via Newsfile

OS Therapies Announces Filing Form S-1 of OS Animal Health Subsidiary

January 14, 2026

Via Newsfile

Frequently Asked Questions

Is OS Therapies Incorporated Common Stock publicly traded?

Yes, OS Therapies Incorporated Common Stock is publicly traded.

What exchange does OS Therapies Incorporated Common Stock trade on?

OS Therapies Incorporated Common Stock trades on the New York Stock Exchange

What is the ticker symbol for OS Therapies Incorporated Common Stock?

The ticker symbol for OS Therapies Incorporated Common Stock is OSTX on the New York Stock Exchange

What is the current price of OS Therapies Incorporated Common Stock?

The current price of OS Therapies Incorporated Common Stock is 1.800

When was OS Therapies Incorporated Common Stock last traded?

The last trade of OS Therapies Incorporated Common Stock was at 06/03/26 08:00 PM ET

What is the market capitalization of OS Therapies Incorporated Common Stock?

The market capitalization of OS Therapies Incorporated Common Stock is 10.53M

How many shares of OS Therapies Incorporated Common Stock are outstanding?

OS Therapies Incorporated Common Stock has 11M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.